Testosterone – is too much better than too little?

heart.jpgResearch findings released this week indicate that men should worry about low testosterone levels. It could be responsible for more than just mood swings and a low sex drive.

Low testosterone levels seem to be linked to a heightened risk of premature death from heart disease and all causes, suggests research published online in Heart journal.

This finding refutes previous research published on the subject, which had indicated that the hormone is a risk factor associated with cardiovascular disease.

The heart health of 930 men was tracked over 7 years, after each had been diagnosed with having coronary artery heart disease.

Low testosterone levels were fairly common in these men; one in four were also diagnosed as having clinically defined testosterone deficiency. This is known as hypogonadism and does not refer to men with declining levels of testosterone due to advancing age.

During the monitoring period almost twice as many men with low testosterone died as did those with normal levels. One in five (41) of those with low testosterone died, compared with one in eight (12%) of those with normal levels.

A clinically defined deficiency in testosterone was an independent risk factor for premature death from all causes and from heart disease, after taking account of other influential factors, such as age, other underlying health problems, smoking and weight

It was found that those men with a borderline- low level of testosterone were also at an increased risk of early death.

The authors have pointed out, while high doses of testosterone delivered by anabolic steroids are hazardous to the health, low rather than high testosterone levels are connected to a whole host of health problems, including obesity and insulin resistance – known risk factors for diabetes and heart disease.

The authors of the study, based at Royal Hallamshire Hospital in Sheffield, have concluded that men with hypogonadism (also at increased risk of the abovementioned conditions) could benefit from testosterone replacement.

A response to this study has highlighted the need for further research into the impact of testosterone on the health of both men and women. The impact or connection of testosterone levels on heart disease has largely taken a backseat, with researchers focusing on the impact of the female hormone Oestrogen until recently.

High testosterone has been linked to a variety of heath issues in women – including increased risk of developing diabetes and cardiovascular disease.

If you would like to read more about the impact of low and high testosterone levels you can take a look at the recently released research, links below.

Research http://press.psprings.co.uk/heart/october/hrt195412.pdf
Editorial response http://press.psprings.co.uk/heart/october/hrt207068.pdf

Men are blind to beauty when it comes to mating


Amsterdam: Men are blind to beauty when it comes to mating opportunities, new research confirms.

Human testosterone triggers an automatic reaction which has evolved in man when faced with a woman, to look for mating opportunities, and it does not matter if the woman is not attractive, the research reveals.

Research involving a group of male students found that their levels of the hormone testosterone increased to the same extent whether they were talking to a young woman they found attractive – or to one they didn’t fancy much at all.

After 300 seconds alone in the same room as a woman they had never met before, and in some cases did not find particularly attractive, the men’s testosterone levels of the hormone had shot up by an average of around eight percent.

The rising levels may then fuel more visible changes in male behaviour that occur in the presence of a woman, including a squaring of shoulders, an upright posture, and greater use of hands – and even, it is suggested, a flaring of the nostrils.

The rise in the male hormone may also be the reason why men are more likely to tell women exaggerated stories about their job, career, education and earnings, the researchers believe.

The study, published in the journal Hormones and Behaviour, involved 63 male students aged 21 to 25 who were not aware of the purpose of the study.

Men who were rated as more aggressive or dominant types had registered even higher testosterone levels. The results also show that testosterone levels did not change when they were in the room with another man.

Leander van der Meij, who led the study at the University of Groningen in Holland, said: “We found a testosterone increase after only five minutes of exposure to a woman. Our results suggest that the increase in testosterone levels that we found, may be an automatic male response that activates receptors in organs and the nervous system to prepare the human body for mate attraction.”

The Telegraph quotes him as saying: “Once levels have risen, they can display more dominant behaviour. They talk more with their hands, there is more eye contact, their posture is more upright, and they are more likely to tell stories designed to impress the woman. We know that women can be attracted by these kinds of things. All this, we believe, may be fuelled by the rise in testosterone that we have found.”

Men with low-testosterone suffer increase in bone fractures


Sydney: Elderly men with low levels of testosterone are more than twice as likely to suffer bone fractures as those with higher amounts of the sex hormone, researchers in Australia found.

A study of men at least 60 years old found a quarter had testosterone deficiency linked to a two-fold increase in the risk of bone fractures caused by osteoporosis, according to researchers at Sydney’s Garvan Institute of Medical Research. The finding may enable doctors to identify susceptible elderly men and devise strategies to prevent bone fractures.

Osteoporosis, when bones thin and break easily, affects 10 million Americans and is generally considered a women’s disease. While women’s bones become fragile after menopause when they stop producing estrogen, men’s weaken at a later age and can cause just as much damage. In Australia, 30 percent of the 110,000 osteoporosis-induced fractures that occur each year are in men.

John Eisman, Professor Medicine at the University of New South Wales and director of Garvan’s bone and mineral programme said: “Osteoporosis in men is basically ignored. This is something that gives us more insight into why they might have problems, why they might be likely to fracture.”

In the US, for example, two million men have the disease and another 12 million are at risk for it, the National Osteoporosis Foundation estimates. Treating patients with osteoporosis medicines including Eli Lilly & Co.’s Evista and Forteo, Merck & Co.’s Fosamax and Procter & Gamble Co.’s Actonel may prevent fragility fractures if the disease is diagnosed early, previous studies have shown.

Each year, about 329,000 hip fractures occur in the U.S. About 20 percent of the people die within six to 12 months after breaking hips, according to a study published in November in the Journal of the American Medical Association.

Men’s testosterone levels are usually about 300 to 1,000 nanograms per deciliter of blood, according to the U.S. National Institutes of Health. A quarter of men over 60 had levels of 294 nanograms or less in the Garvan study, which followed 609 men aged over 60 years between January 1989 and December 2005.

Even after adjusting for factors known to alter fracture risk, including age, weight, fracture history, smoking status and calcium intake, the risk of fracture was more than doubled in men with low testosterone compared with men with high levels of the hormone, according to the study. The results were published yesterday in the Archives of Internal Medicines.

“Men with lower testosterone might be getting a double whammy,” Eisman said. “Their bones are worse and their muscles are a bit weaker, both of which are likely then to contribute to their risk of fractures.”

While testosterone supplements may assist those deficient in the hormone, other treatments may also help, he said.

“Importantly, reducing alcohol consumption, avoiding smoking, maintaining an active lifestyle, getting sunlight exposure and eating a diet rich in calcium will also help to minimize risk,” Eisman said.

The research is part of the Dubbo Osteoporosis Epidemiology Study, which started in 1989 and recruited all men and women 60 years or older living in Dubbo, a regional city of 32,000 predominantly white people in Australia’s New South Wales state.

Men with higher levels of testosterone may live longer, suggests new research

San Diego: Men with higher levels of the hormone testosterone may live longer, according to a new study.

Men with low testosterone levels tend to have fatter waists, high blood pressure and higher blood sugar levels, researchers found.

Those with high levels of the male sex hormone tended to have a lower risk of heart disease and diabetes in later life.

The study – the first of its kind to look at normal, relatively fit males – could lead to men with low levels taking supplements.

The survey followed the lives of 800 men aged over 51 since the 1970s. It found that those with low testosterone levels were a third more likely to die over an 18-year period than those with high testosterone levels.

The results cast doubt on the popular wisdom that the female hormone, oestrogen, is “good” for health in later life and testosterone is ‘bad’. According to the research team at the San Diego School of Medicine, the discrepancy could not be explained by pre-existing diseases such as diabetes or heart disease.

Dr Gail Laughlin, from the school’s Department of Family and Preventative Medicine, said: “We have followed these men for an average of 18 years and our study strongly suggests that the association between testosterone levels and death is not simply due to some acute illness. The study did show there may be an association between low testosterone levels and higher mortality.”

She cautioned that the study did not directly show that higher testosterone levels protected against diseases.

Testosterone declines slowly with age. However, there is a wide natural variation in the amount that different men produce.

The researchers said that besides tending to have larger waists and higher blood pressure, men low in testosterone had higher levels of inflammatory cytokines, proteins that contribute to the development of many diseases.

The San Diego School of Medicine is now considering trials of testosterone supplements to see if they have a preventative effect.

However, Dr Elizabeth Barrett-Connor, of the San Diego School of Medicine’s Division of Epidemiology, said the prospect of men popping testosterone pills to protect against diseases was a long way off.

She said: “We are very excited about these findings, which have important implications, but we are not ready to say that men should go out and get testosterone to prolong their lives.

She also said that low testosterone levels could be a by-product of obesity and suggested it may be possible to alter testosterone levels by lowering obesity.

DHEA – anti-ageing experts criticise flawed report

Fort Lauderdale: The war between those who advocate natural approaches to disease prevention as opposed to proponents of synthetic drugs continues unabated. At stake are the lives of millions of aging humans who are confronted with institutional propaganda aimed at discrediting therapies that are not FDA approved.

As health-conscious Americans are well aware, a large volume of published research documents significant benefits when aging humans restore DHEA and testosterone hormones to youthful levels.

On October 19, 2006, however, the media reported on a very small study that showed only miniscule results in aging humans who received either DHEA or low-dose testosterone. In response to this one study, the media declared that these hormones are “no fountain of youth”.1

This one study showing only small benefits to DHEA or testosterone supplementation had serious design flaws that invalidate its conclusions. The newscasters failed to consider these flaws when proclaiming there is “no reason for older people to continue taking DHEA.”

In todayÂ’s media frenzied world, scientific journalism is practiced by ambush. The very day a medical study is published, it can become the headline news story of the day. This denies an opportunity for those who might disagree with the studyÂ’s design and methodologies to rebut what might be junk science. In the case of this recent study questioning the use of DHEA and testosterone, the flaws are so significant as to cause its findings to have little or no meaning.

This article represents Life ExtensionÂ’s initial rebuttal to the recent attack on DHEA and testosterone.

Flaw Number One: Factors Affecting Bone Mass Ignored

One of the anti-aging parameters tested in this study was the effects of DHEA or testosterone on bone mineral density.

Compared to placebo, the study found that in women supplemented with DHEA, there was a small, but significant increase in bone mineral density of the ultradistal radius (a wrist bone). Men who supplemented with DHEA had a small, but significant increase in the bone mineral density of the femoral neck. (The “femoral neck” connects the shaft of the femur bone to the ball part of the femur in the hip.)

Men who supplemented with testosterone had a significant increase in the bone mineral density of the femoral neck. No increase in bone mineral density was found in the spine or total femur in those who supplemented with DHEA or testosterone.

Based on these findings, the media declared DHEA and testosterone worthless, despite the fact that there was improvement in several measurements of bone mineral density. When viewed in the context of data from previous studies showing significant bone benefit in response to DHEA-testosterone, the findings from this recent study help confirm the effects that these two hormones confer on bone health.

The biggest problem with this study parameter, however, is that it only looked at DHEA or testosterone compared to placebo. It did not monitor the study subjects to ascertain what else they might be doing that would affect their bone density.

As any health-conscious consumer knows, there are many more factors involved in maintaining bone density than just DHEA and testosterone. The study failed to assess diet or the intake of nutrients involved in bone density such as calcium, vitamin D, magnesium, and vitamin K when comparing those who took DHEA or testosterone to the placebo group.

Due to the small size of this study (87 men and 57 women), there is a very real chance that there were differences in terms of bone-protecting nutrient intake between the two groups. This means that it is possible that subjects in the placebo arm may have taken more calcium, vitamin D, vitamin K, magnesium, etc. than those in the DHEA and/or testosterone group. The failure to specifically control for bone-building nutrient intake points to one of several flaws in the study design.

Flaw Number Two: Factors Affecting Body Composition Ignored

Another anti-aging parameter this study looked at was the effects of DHEA or testosterone on body fat and muscle mass.

Compared to placebo, elderly men supplemented with DHEA had a decrease in the proportion of body fat (as measured by fat-free mass). When the male and female groups were combined, the DHEA group had a small but significant decrease in the proportion of body fat. Men in the testosterone group had a significant reduction in body fat (as measured by fat-free mass).

These findings confirm previous studies showing reductions in body fat in those supplementing with DHEA or testosterone. For example, a recent 2004 study showed that DHEA supplementation in aging men and women was associated with significant reductions in abdominal fat as well as improvements in insulin sensitivity.2

When measuring another area of body composition, women receiving DHEA showed a 9.2 cm2 increase of lean thigh muscle area compared to a 3.5 cm2 decrease in the placebo group. However, because women in the placebo group already had higher thigh-muscle area than in the DHEA group at baseline, the study authors concluded that DHEA had no effect on thigh-muscle area. This conclusion is particularly biased when one considers that lean muscle mass in the thigh of women treated with DHEA was higher than the placebo group at the end of the study, even though the DHEA group had a less lean muscle mass at the beginning of the study compared to placebo.

Despite these favorable body composition findings, the media stated that consumers who bought DHEA supplements were receiving no value. Not only is this another false conclusion, but the failure of the study design to assess calorie intake, types of calories consumed, and other factors involved in body fat composition renders even these modest reductions in body fat highly suspect. In other words, since this was such a small study, if just a few participants in either the DHEA or testosterone group increased calorie intake, or altered their diet to cause increases in body fat, this could have skewed the results significantly. If on the other hand, just a few participants in the placebo group reduced their calorie intake, this would have distorted the final results even more.

Further twisting the findings related to body composition was the criteria that excluded anyone from participating in the study who engaged in exercise lasting more than 20 minutes more than two times a week. Exercise is an important component of an anti-aging program, and excluding those who regularly engage in exercise helped ensure that neither the active or placebo group would demonstrate significant changes.

We know that DHEA works to enhance the benefits of exercise. For example, a recent study showed that DHEA potentiated the effect of 4 months of weight-lifting training on muscle strength and on thigh muscle mass.3

The failure of the study design to incorporate both DHEA and exercise to build bone and muscle mass is embarrassing from a scientific standpoint, and highlights another defect in the trial design.

Flaw Number Three: No Individualized Program

In this recent study, all participants received the exact same dose of DHEA or testosterone for two straight years. It did not matter if individual blood levels skyrocketed too high or failed to even reach minimum levels needed to achieve efficacy. As far as the designers of this study were concerned, one size (i.e., the same dose) fits all.

Hormone requirements vary considerably between individuals. Some people, for instance, only need 15 mg/day of DHEA, while others require over 100 mg/day to attain similar blood levels. In this study, all male participants in the active group were given 75 mg/day of DHEA or 5 mg/day of transdermal testosterone. All women participants in the active group were given 50 mg/day of DHEA.

Based on reviewing thousands of blood test results of people taking DHEA and/or testosterone, Life Extension researchers have observed huge variations in individual responses to DHEA and testosterone supplemental intake. This has also been confirmed by the hundreds of practicing physicians who prescribe these hormones and then do follow-up blood tests to make sure their patients achieve optimal hormone balance.

There was no attempt to achieve optimal blood levels of DHEA or testosterone in these study participants. The sole objective of this study was to give each participant in the active group the exact same dose of hormone(s) and then monitor some of the effects compared to placebo. We at Life Extension view the failure to use blood test results to adjust individual hormone dosing as the equivalent of target shooting while blindfolded and then saying it is impossible to consistently hit the target.

The fact that the conventional doctors who designed this study failed to factor in the need for individualized dosing is not surprising. For decades, physicians have prescribed the same dose of estrogen and other drugs to patients regardless of individual need. Despite the existence of millions of copies of books that specify how DHEA-testosterone should be properly dosed, the doctors who designed this flawed study failed to adjust the amount of DHEA-testosterone given to study subjects based on individual blood readings. Nor was there even a mention of the fact that doctors who prescribe these hormones do indeed adjust doses based on blood or saliva test results.

The flawed methodology applied to dosing DHEA and testosterone from this trial is another defect in trial design. Yet, this egregious error did not stop the headline hungry media from vilifying DHEA and testosterone.
Flaw Number Four: Failure to Suppress Excess Estrogen
As men mature past age 50, an enzyme called aromatase increases in their bodies.

The aromatase enzyme converts testosterone to estrogen. When testosterone drugs are given to aging men, the aromatase enzyme can convert the testosterone into excess estrogen, which causes undesirable effects.
One problem with excess estrogen in aging men is that the balance of testosterone to estrogen is disrupted, with the excess estrogen contributing to feminizing effects in aging men.

In the study the media used to attack DHEA-testosterone, levels of estrogen increased dramatically in both men and women in the active group as opposed to the placebo group. Instead of carefully assessing individual response and taking steps such as reducing the dose of DHEA or prescribing aromatase-inhibitors (such the drug Arimidex® or nutrients like zinc, nettle, and chrysin) in response to high estrogen levels, many study participants were allowed to continue with undesirably high estrogen levels.

Interestingly, some beneficial effects were shown in the active (DHEA or testosterone) groups, despite the high levels of estrogen that manifested. Had aromatase inhibitors been used in the male group where appropriate, and DHEA dosing reduced in the female group when estrogen levels increased too much, the beneficial effects of DHEA or testosterone could have been exponentially enhanced.
The failure to protect against excess estrogen production in response to DHEA or testosterone therapy invalidates this studyÂ’s findings. The media, however, never gave the experts on anti-aging medicine an opportunity to point out this significant flaw.

The mediaÂ’s biased assassination of DHEA-testosterone will result in most aging Americans remembering their newscaster proclaiming that hormone restoration is a waste of money. There was no scientific debateÂ…just a public relations coup by todayÂ’s prescription drug-financed medical establishment.

Flaw Number Five: Testosterone Not Restored to Youthful Levels

In studies showing dramatic anti-aging effects in response to testosterone therapy, levels of testosterone were restored to youthful ranges (500-1200 ng/dL). Subjects receiving testosterone in this recent flawed study only increased their total blood testosterone levels from 357 ng/dL to 461 ng/dLÂ… well below optimal youthful ranges.

Median levels of biologically active free testosterone remained below normal youthful ranges throughout the study and did not reach the higher levels recommended by anti-aging experts.

The authors of the study acknowledged that they gave these men low doses of testosterone when stating in their conclusion: “Additional long-term studies of testosterone are warranted to determine the risk-benefit ratio of higher doses.”

Despite the obvious failure to adequately increase testosterone blood levels, the media participated in this hoax to deceive American men into believing that they should not replenish the testosterone lost to aging. This is great news for pharmaceutical companies who stand to sell a lot more prescription drugs that treat associated problems related to suboptimal hormone levels such as sexual health, depression, cardiovascular health, neurological disorders, and the many chronic inflammatory conditions that can all be effectively prevented by correcting the underlying hormonal deficiency in the first place.

Flaw Number Six: Inadequate Numbers of Study Subjects to Assess Quality of Life.

Another anti-aging parameter of this study looked at quality of life scores and found no improvement.
Previous studies, however, tested these hormones on people suffering from depression and other quality of life problems. These previous studies showed that DHEA or testosterone was effective in people who suffered from these disorders. For example, a 2005 study showed that in middle-aged men and women suffering from minor and major depression, DHEA significantly reduced depression scores and improved sexual function scores as against the placebo group.4

The fact that individuals not suffering from these disorders did not report improvements in their quality of life scores could have been due to faulty data collection or the very small study size.

In fact, the editorial that accompanied this study stated that there were too few subjects enrolled to detect clinically meaningful differences in this quality of life parameter. This same editorial, however, also called for DHEA to be regulated as a prescription drug.

Flaw Number Seven: Inadequate numbers of study subjects to assess effects on glucose control

Type II diabetes is characterized by systemic insulin resistance that results in chronic hyperglycemia (excess blood sugar). Previous studies indicate that DHEA and testosterone protect against insulin resistance. For example, a 2003 trial showed that 25 mg of DHEA improved insulin sensitivity as well as endothelial function in hypercholesterolemic men.5

In this study on healthy people, DHEA or testosterone did not improve markers related to insulin resistance. The fact that the study size was very small may explain why the finding of this study parameter was neutral.

Flaw Number Eight: Increases in Physical Strength Downplayed
Compared to baselines, men and women taking DHEA could chest press 4.99 pounds more weight than the placebo group after two years. Men receiving low-dose testosterone were able to chest press 9.99 more pounds compared to the placebo group after two years.

The studyÂ’s authors downplayed these improvements by stating three months of resistance exercise training increased chest press strength by an average of 33 pounds in older people.

The contradiction is that the study subjects were not allowed to participate in more than 20 minutes of exercise more than two times a week. This restriction would have severely limited an improvement in physical strength, yet even with this exercise restriction, there was still a measurable improvement in physical strength in those receiving DHEA or testosterone compared to placeboÂ…a fact the media choose to ignore when attacking the use of these hormones for anti-aging purposes.

Flaw Number Nine: It Takes More Than Hormones to Slow Aging Parameters

There are 14 independent causes of aging that have been identified. The good news is that there are ways of at least partially protecting against each one of these 14 different causes of age-related degeneration.

As has been the case with previous flawed studies, conventional doctors restrict test subjects to a single approach that might beneficially affect some aging parameters. When that single approach fails to produce significant results, the medical establishment (and the media) proclaims the nutrient or hormone to be worthless.

Patients that visit anti-aging doctors for hormone replacement therapy are prescribed a lot more than just DHEA or testosterone. They are often put on comprehensive programs that involve dietary changes, exercise, synergistic hormone modulating drugs-nutrients, replacement of other hormones lost to aging (like progesterone, pregnenolone, thyroid), and dietary supplements (like CoQ10, carnitine, lipoic acid, carnosine, fish oil) that address specific age-accelerating mechanisms.

The design of this study virtually guaranteed failure since it only provided subjects with DHEA or low-dose testosterone. An absolute consensus amongst those in the anti-aging community is that a lot more than sub-optimal hormone therapy is required to slow and partially reverse aging, though proper hormone balancing is a critical component of an overall program.

The appendix at the end of this article articulates the 14 independent causes of aging and what can be done to partially counteract them. When reviewing these pathological mechanisms involved in normal aging, it would be absurd to assume that miraculous results could be obtained by correcting only one of them (i.e. hormone imbalance), as was done in this flawed study.

Flaw Number Ten: Study Did Not Evaluate All of DHEAÂ’s Effects

Conventional doctors and the media took the mediocre findings from this flawed study and concluded that DHEA or testosterone replacement is of no value to elderly humans. Yet the parameters used in the study to assess aging were limited to:
1. Bone mineral density
2. Body fat-muscle composition
3. Quality of life scores
4. Insulin resistance and glucose tolerance
5. Physical performance

Despite the failure to customize the dose of DHEA or testosterone based on individual need, the failure to protect against excess estrogen, the failure to assess for other independent factors (such as the effect of food intake on body fat mass), the failure to achieve optimized blood levels of these hormones, and the failure to account for nutrients needed to maintain or restore these narrow parameters of aging (such as whether test subjects were taking calcium/vitamin D to build bone), there was still some benefit shown in the DHEA and testosterone groups.

What was blatantly omitted from the attack on DHEA-testosterone was the fact that aging individuals take these hormones for purposes that go beyond the narrow parameters evaluated in this study. For instance, DHEA has long been used to help maintain neurological, sexual, and immune function in those going through normal aging processes and those afflicted with certain disorders. The most striking benefit associated with DHEA (and testosterone), however, may have to do with protecting against endothelial dysfunction that can lead to heart attack, stroke, and other vascular diseases.

How many lives might be lost?

The two-year study used to vilify DHEA only had 87 male participants, with one-third of the subjects receiving placebo. Based on this one study, conventional doctors are calling for DHEA to be removed from the marketplace and turned into a prescription drug. There were no adverse effects reported during this study.

Overlooked by the media are the hundreds of studies showing significant benefits to those who maintain higher DHEA or testosterone blood levels. For example, in a larger study involving 1,700 aging males carried out over nine-years, those with the lowest levels of DHEA were 60% more likely to develop coronary artery disease.6

About one million people die from a vascular-related disease each year

Compelling evidence indicates that many of these deaths could be prevented if aging men maintained their DHEA and testosterone in more youthful ranges. If DHEA-testosterone reduced these deaths by only 20%, then about 200,000 American lives could be saved each year.

DonÂ’t Be a Victim of Drug Company Propaganda

In response to this flawed study, conventional doctors are calling for the FDA to regulate DHEA as a prescription drug. Despite this study showing no adverse effects from DHEA or testosterone, the rationale is that people are being “ripped off” when they are sold these hormones for anti-aging purposes. This drastic conclusion flies in the face of hundreds of published studies validating the anti-aging benefits in response to DHEA and testosterone restoration.

There is little subtlety in what these mainstream doctors are really trying to accomplish. They make it clear that based on this one study, prescription “bisphosphonate” drugs would re-build bone better than natural hormone replacement. While bisphosphonate drugs have a role in preventing cancer metastasis to the bone, they are very expensive and cause serious side effects in some people. DHEA, on the other hand, is so cheap it is difficult to credibly claim that anyone is being “ripped off” when buying it, as one doctor was quoted as stating.

It is in the economic interest of the pharmaceutical industry to see restrictions placed on DHEA and testosterone as there would be a surge of age-related diseases if free access to these hormones were to be denied. This increase in age-related disease would directly correlate with the widespread deficiencies of DHEA and testosterone that would occur if consumer access to these hormones was impeded by governmental edict.

Financial Conflicts of Interest

Some of the authors of the flawed study on DHEA and testosterone have connections to the pharmaceutical industry, and drug money lobbyists can heavily influence how these studies are designed.

The doctor who most viciously attacked DHEA, stating that consumers were being “ripped-off” when buying it, admitted to receiving consulting fees and/or grants from drug companies that include Pfizer, Novo Nordisk, Novartis, and Duocort.7

While all these companies sell drugs whose sales would be adversely affected if more people used DHEA, the Duocort pharmaceutical company’s website specifically states that it is developing drugs aimed at “chronic adrenal hormone replacement therapy.” DHEA is synthesized primarily in the adrenal glands. DHEA is used by aging people because after age 30, there is a chronic deficiency in adrenal DHEA production.

While DuocortÂ’s public focus is on developing long-acting glucocorticoid drugs to treat adrenal insufficiency, it seems more than a coincidence that the most vocal critic of DHEA supplements has received consulting fees from a company whose website states:

“Treatment of adrenal insufficiency involves replacing, or substituting, the hormones that the adrenal glands are not making.”
Based on conventional medicineÂ’s logic, it is alright to replace hormones (like DHEA) the adrenal glands are not making as long as the replacement is a patented prescription drug. The news media totally overlooked these financial conflicts of interest when regurgitating the anti-DHEA propaganda of doctors on the payroll of the pharmaceutical industry.


In response to a plethora of positive studies linking higher DHEA levels to lower degenerative disease risk,8-33 DHEA has become an enormously popular low cost dietary supplement. The use of testosterone enhancing products by aging men has aalso grown exponentially over the past decade.

An evaluation of the recent study that questions the anti-aging efficacy of DHEA and testosterone reveals serious flaws that invalidate the studyÂ’s findings. Despite these flaws, the actual findings show a small but significant benefit to DHEA-testosterone when measuring certain parameters related to aging.

The media choose to downplay the benefits demonstrated in this study and instead launched an attack against the use of DHEA-testosterone for anti-aging purposes.
Proponents of natural hormone restoration have been very clear about the need to achieve optimal levels of testosterone and DHEA. The subjects in this recent study were not individually dosed and therefore did not come anywhere close to achieving optimal blood levels. It is thus no surprise that the results of this flawed study are inconsistent with the known health benefits of DHEA.

The financial existence of drug companies is dependent on substantial numbers of aging Americans contracting degenerative diseases. Drug companies therefore have an economic interest in finding ways to discourage and even criminalize the use of youth hormones that protect against age-related disease. For instance, if DHEA and testosterone supplementation only lowered cardiovascular disease rates by 20%, the drug industry would face billions of dollars in lost profits, as sales of drugs used to treat vascular diseases would be correspondingly reduced.

In an attempt to discredit the benefits of natural hormone restoration, conventional doctors, some with direct financial links to the pharmaceutical industry, sought to mischaracterize the findings from this very small and flawed study on elderly men and women.

The downplaying of the beneficial findings found in this study, along with ten specific flaws that invalidate its results, represents a biased attempt to discourage aging Americans from maintaining or restoring youthful hormone balance.

Diet rich in soy cuts prostate cancer risk

Honolulu: Research carried out by the Cancer Center of Hawaii has found that just two daily servings of soy reduced levels of the prostate cancer marker PSA in men by 14 percent.

Doctors test PSA (prostate-specific antigen) levels in men to screen for prostate cancer. The Hawaii indings support previous studies which suggest that soy may reduce the risk of prostate cancer development and progression.They also show that levels of the male hormone testosterone were unaffected. The results of the new randomized, crossover clinical trial, are published on-line in the European Journal of Clinical Nutrition

The isoflavones of soy are phytoestrogens and exert mild estrogen-like action.

The researchers at the Cancer Research Center of Hawaii, recruited 23 men with an average age of 58.7 and randomized them to receive either a high soy diet of two servings of soy per day or a low soy diet normal diet for three months. The the first test period, was followed by a one-month break and then the men crossed over to eat the other diet for a further three months.

The research adds to a growing number of studies linking soy-containing diets to lower incidences of prostate cancer. But longer and larger trials are needed to confirm or challenge these findings.

There are over half a million news cases of prostate cancer that are diagnosed every year world wide, and the cancer is the direct cause of over 200,000 deaths. The incidence of the disease is also increasing with a rise of 1.7 per cent over 15 years.

The lowest incidences of the cancer are found in China, Japan and India, with experts linking this to a high dietary intake of soy products. A recent meta-analysis from the International Journal of Cancer reported that men who regularly consumed soy-containing products had a 30 per cent lower risk of the cancer.